Firmagon 80mg Injection contains degarelix, a gonadotropin-releasing hormone (GnRH) antagonist used primarily in the treatment of advanced prostate cancer. By competitively binding to GnRH receptors in the pituitary gland, Firmagon effectively suppresses the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a rapid decrease in testosterone levels, which is crucial for managing hormone-sensitive prostate tumors. Unlike GnRH agonists, Firmagon does not cause an initial surge in testosterone, thereby reducing the risk of tumor flare and associated symptoms. The injection is administered subcutaneously, typically starting with a loading dose followed by monthly maintenance doses, ensuring sustained suppression of testosterone. Firmagon is indicated for patients with advanced hormone-dependent prostate cancer who require androgen deprivation therapy. Common side effects may include injection site reactions, hot flashes, weight gain, and elevated liver enzymes. It is important to monitor patients for potential cardiovascular events and liver function abnormalities during treatment. Firmagon offers a targeted approach to hormone therapy, improving patient outcomes by quickly reducing testosterone levels without the flare effect seen with other treatments. Proper administration and adherence to dosing schedules are essential for optimal therapeutic efficacy.